SEP 08, 2020 9:30 AM PDT

New Drug Boosts Bone Growth in Children with Dwarfism

WRITTEN BY: Annie Lennon

A Phase III global clinical trial by the Murdoch Children’s Research Institute (MCRI) has found that a new drug, known as vosoritide, is able to increase bone growth in children with achondroplasia, the most common type of dwarfism. 

A genetic bone disorder, achondroplasia, is known to affect around 250,000 people globally or approximately 1 in every 25,000 children. The condition is caused by overactivity of the FGFR3 protein, which reduces bone growth in children’s limbs, spine, and the base of the skull. Rather than growing 6-7 cm per year, children with the condition grow an average of 4cm per year. Current treatments for the condition, which include surgery, only address symptoms of the disorder.

Vosoritide, on the other hand, directly targets the molecular cause of the disease. It works by blocking the protein’s activity, ultimately returning growth rates to normal. While previous trials by MCRI showed that the drug is safe in young people with dwarfism, the new trial shows that it is also able to increase bone growth over one year with daily injections. 

For the randomized, placebo-controlled trial, researchers enrolled 121 children aged between 5 and 18 in 24 hospitals across seven countries. All in all, the researchers found that the the 60 children who received daily injections of vosoritide grew an average of 1.57 cm more than children who received the placebo- bringing their growth rates more or less in line with peers who do not have the disorder. 

The researchers did note, however, that the drug did not significantly improve the proportions between their upper and lower bodies. Nevertheless, the children will be followed until they reach their final adult height to see whether the drug’s effects are long-lasting and whether they have a growth spurt during puberty- something that is unusual among children with achondroplasia. 

Nevertheless, BioMarin Pharmaceutical, the manufacturer of the drug and funder of the trial, has applied to the US Food and Drug Administration to license vosoritide as a treatment for achondroplasia. The company also applied to the European Medicines Agency, which has since approved their application. 

 

SOurces: MecialXpressEurekAlert

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 04, 2020
Cancer
Building a New Chemotherapy Drug
NOV 04, 2020
Building a New Chemotherapy Drug
For decades, modern medicine has relied on chemists’ work to produce compounds that could one day be used as a dru ...
DEC 08, 2020
Immunology
Drug Targets Cold Tumors' Achilles Heel
DEC 08, 2020
Drug Targets Cold Tumors' Achilles Heel
Immunotherapies have emerged as a powerful treatment modality for cancer. They join chemotherapy, surgery, radiotherapy, ...
DEC 21, 2020
Drug Discovery & Development
Drug Increases Vaccine Responses
DEC 21, 2020
Drug Increases Vaccine Responses
A drug was found to increase the effects of vaccine responses in older adults. The drug works by removing cellular debri ...
DEC 24, 2020
Drug Discovery & Development
New Gene Therapy Targets Deafness
DEC 24, 2020
New Gene Therapy Targets Deafness
New gene therapy study addresses treatment methods for deafness. "In this study we focused on genetic deafness caus ...
DEC 30, 2020
Neuroscience
Do Psychedelics Reduce Trauma from Racial Injustice?
DEC 30, 2020
Do Psychedelics Reduce Trauma from Racial Injustice?
Researchers from Ohio State University have found that a single positive experience on psychedelics may reduce stress, d ...
JAN 01, 2021
Microbiology
A New Type of Antibiotics Help the Immune System Fight Pathogens
JAN 01, 2021
A New Type of Antibiotics Help the Immune System Fight Pathogens
Reporting in Nature, scientists have identified a new group of compounds that may help us get out of the antibiotic-resi ...
Loading Comments...